Showing 3781-3790 of 7375 results for "".
- Galderma Moves to Differentiate Their Two New HA Fillers From The Frayhttps://practicaldermatology.com/news/galderma-moves-to-differentiate-their-two-new-ha-fillers-from-the-fray/2458262/With a growing number of hyaluronic acid (HA) fillers available and even more in the pike, Galderma is highlighting how their two newest fillers --Restylane Refyne and Restylane Defyne --stand out from the crowd. In a word: flexibility. Th
- Modernizing Medicine and Galderma Team Up to Offer Integrated OTC eCommerce Platformhttps://practicaldermatology.com/news/modernizing-medicine-and-galderma-team-up-to-offer-integrated-otc-ecommerce-platform/2458264/Specialty-specific health information technology company Modernizing Medicine, Inc. and Galderma Laboratories, L.P. are collaborating to deliver new capabilities in support of improved patient experiences and outcomes through healthcare provider recommended over-
- Sunburn Risk May Be Greatest in Skin of Colorhttps://practicaldermatology.com/news/sunburn-risk-may-be-greatest-in-skin-of-color/2458271/Sunburn risk is greatest for young adults with melanin-rich skin, according to a study published in The Journal of the American Osteopathic Association. Researchers found a surprising correlation between reporting a red
- Obagi Medical Products Collaborates with Suzan Obagi, MD and Nextcell Medical to Introduce New Linehttps://practicaldermatology.com/news/obagi-medical-products-collaborates-with-suzan-obagi-md-and-nextcell-medical-to-introduce-new-line/2458274/Valeant Pharmaceuticals International, Inc.’s wholly owned subsidiary Obagi Medical Products collaborated with Nextcell Medical Company to claim exclusive distribution of Suzan Obagi, MD’s line of skin care products throughout the United States. Established in 2013 with cosmetic
- Cloudy With a Chance of Wrinkles: Most Americans Fail to Protect Skin From Pollutionhttps://practicaldermatology.com/news/cloudy-with-a-chance-of-wrinkles-most-americans-fail-to-protect-skin-from-pollution/2458275/Most Americans don’t protect their skin from pollutants even though they are aware of the harm that pollution and other environmental stressors can cause to skin, according to a new survey by H2O+ Beauty. Just 33 percent of people purchase
- Vision Medical's SmartGraft Now Offers Articulating Arm With Mayo Trayhttps://practicaldermatology.com/news/vision-medicals-smartgraft-now-offers-articulating-arm-with-mayo-tray/2458276/SmartGraft® Hair Restoration is rolling out its first articulating arm and mayo tray, Vision Medical Inc., reports. Available in February, the SmartGraft AMT (articulating mayo tray) provides ergonomic design for physicians Available to ne
- Suzanne Olbricht, MD, Named New Chief of Dermatology at Beth Israel Deaconess Medical Centerhttps://practicaldermatology.com/news/suzanne-olbricht-md-named-new-chief-of-dermatology-at-beth-israel-deaconess-medical-center/2458278/Suzanne Olbricht, MD, is the new Chief of Dermatology at Beth Israel Deaconess Medical Center (BIDMC) in Boston. She will also serve as President of the American Academy of Dermatology in 2018. From 1983 to 1997, Dr. Olbricht worked as a staff derma
- Researchers Discover New Antibiotic That May Fight MRSAhttps://practicaldermatology.com/news/researchers-discover-new-antibiotic-that-may-fight-mrsa/2458282/Researchers at the University of East Anglia (UEA) and the John Innes Centre (JIC) have uncovered a new antibiotic that they say is potent against antibiotic-resistant ‘superbugs’ like methicillin resistant Staphylococcus aureus (MRSA). The researchers isolated
- Deadline Extended for Medical Spa State of the Industry Statistical Studyhttps://practicaldermatology.com/news/deadline-extended-for-medical-spa-state-of-the-industry-statistical-study/2458280/The American Med Spa Association (AmSpa) has extended the deadline for the 2017 Medical Spa St
- FDA Approves Valeant's SILIQ For Moderate-To-Severe Plaque Psoriasishttps://practicaldermatology.com/news/fda-approves-valeants-siliq-for-moderate-to-severe-plaque-psoriasis/2458283/The FDA has approved the Biologics License Application (BLA) for Valeant Pharmaceutical's SILIQ (brodalumab) injection, for subcutaneous use, a monoclonal antibody that targets the IL-17 receptor for patients with moderate-to-severe plaque psoriasis. SILIQ is indicated for the treatment of mo